Tumour necrosis factor-a (TNF) is an inflammatory cytokine that is elevated in a number of autoimmune diseases including immune thrombocytopenia (ITP), a bleeding disorder characterized by low platelet counts. In vitro TNF blockade increases expansion of the regulatory T cell (Treg) IKZF2 (also termed Helios) subset in T cell-monocyte cocultures from healthy donors, but its role on proliferative responses of Tregs in ITP patients, who have altered immunoregulatory compartment, remains unclear. TNF in CD4+ T cells from patients with chronic ITP were elevated and negatively correlated with peripheral Treg frequencies, suggesting a possible inhibitory effect of TNF on ITP Tregs. In vitro antibody neutralization with anti-TNF in T cell-monocyte cocultures resulted in a robust expansion of pre-existing ITP Tregs, higher than in healthy controls. Similar to the effects of anti-TNF antibodies, TNF blockade with antibodies against TNFRSF1B (anti-TNFRSF1B, previously termed anti-TNFRII) almost doubled ITP Treg expansion whereas neutralization with anti-TNFRSF1A (anti-TNFRI) antibodies had no effect on proliferative responses of Tregs. In addition, TNFRSF1B levels on ITP Tregs were significantly elevated, which may explain the increased susceptibility of patient Tregs to the actions of TNF blockade. Altogether, these data raise the possibility that TNF blockers, through their ability to increase Treg proliferation, may be efficacious in ITP patients.
Summary
Tumour necrosis factor-a (TNF) is an inflammatory cytokine that is elevated in a number of autoimmune diseases including immune thrombocytopenia (ITP), a bleeding disorder characterized by low platelet counts. In vitro TNF blockade increases expansion of the regulatory T cell (Treg) IKZF2 (also termed Helios) subset in T cell-monocyte cocultures from healthy donors, but its role on proliferative responses of Tregs in ITP patients, who have altered immunoregulatory compartment, remains unclear. TNF in CD4+ T cells from patients with chronic ITP were elevated and negatively correlated with peripheral Treg frequencies, suggesting a possible inhibitory effect of TNF on ITP Tregs. In vitro antibody neutralization with anti-TNF in T cell-monocyte cocultures resulted in a robust expansion of pre-existing ITP Tregs, higher than in healthy controls. Similar to the effects of anti-TNF antibodies, TNF blockade with antibodies against TNFRSF1B (anti-TNFRSF1B, previously termed anti-TNFRII) almost doubled ITP Treg expansion whereas neutralization with anti-TNFRSF1A (anti-TNFRI) antibodies had no effect on proliferative responses of Tregs. In addition, TNFRSF1B levels on ITP Tregs were significantly elevated, which may explain the increased susceptibility of patient Tregs to the actions of TNF blockade. Altogether, these data raise the possibility that TNF blockers, through their ability to increase Treg proliferation, may be efficacious in ITP patients.
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Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder resulting from the immune destruction of platelets and insufficient platelet production. Anti-platelet autoantibodies are responsible for increased platelet clearance by the reticuloendothelial system and probably for inhibition of megakaryopoiesis (Gernsheimer, 2009) . In addition, a role for cytotoxic T cells in the direct lysis of platelets and megakaryocytes in the bone marrow has been proposed. (Olsson et al, 2003; Zhang et al, 2006; Li et al, 2007) ITP patients harbour platelet-autoreactive T helper (Th) cells with increasing cytokine imbalance towards interleukin 2 (IL2) and c-interferon (IFNG, IFN-c) (Semple & Freedman, 1991; Kuwana et al, 1998; Ogawara et al, 2003) , as well as altered regulatory T cell (Treg) and B cell (Breg) numbers and function (Ling et al, 2007; Liu et al, 2007; Sakakura et al, 2007; Stasi et al, 2008; Yu et al, 2008; Audia et al, 2011; Li et al, 2012; Yazdanbakhsh et al, 2013) . More recently, we found that Treg dysregulation was partly due to increased inhibition of Treg proliferation by ITP CD16+ monocytes through IL12 Yazdanbakhsh et al, 2013) . However, the possibility still remains that other cells or inflammatory cytokines may also contribute to altered Treg compartment in ITP patients.
Tumour necrosis factor-a (TNF) is an inflammatory cytokine that plays a pivotal role in infectious and autoimmune diseases, as evidenced by the successful treatment of these diseases with anti-TNF drugs. Treatment with TNF blockers has only been reported in a small group of patients with ITP, albeit efficacious in all 4 treated patients (McMinn et al, 2003; Litton, 2008) . Higher levels of TNF have been reported in the plasma/serum from ITP patients, (Culic et al, 2013; Jernas et al, 2013; Talaat et al, 2014) although TNF expresresearch paper First published online 24 September 2014 doi: 10.1111/bjh.13126 sion levels in specific ITP cell types, such as CD4+ T lymphocytes, has not been examined. Interestingly, ITP patients have an increased frequency of TNF À308 A polymorphic allele associated with higher TNF-a production (Pehlivan et al, 2011; Sarpatwari et al, 2011; El Sissy et al, 2014) . TNF binds to two distinct receptors: TNFRSF1A (TNFRI, p55) and TNFRSF1B (TNFRII; p75) (Locksley et al, 2001) . TNFRSF1A is ubiquitously expressed on almost all cell types while TNFRSF1B is typically expressed on cells of the immune system including Tregs (Faustman & Davis, 2013) . Surface expression of TNFRSF1B can be induced by IL1B, IL2 and TNF (Carpentier et al, 2004) , cytokines reported to be increased in ITP patients (Rocha et al, 2010; Culic et al, 2013; Jernas et al, 2013; Talaat et al, 2014) , although TNFRSF1B levels on Tregs in ITP patients have not been measured. It is generally accepted TNF can regulate Treg differentiation and proliferation, but the exact outcome appears to depend on Treg subset, the disease setting and the cytokine microenvironment (Biton et al, 2012) . For example, in a murine autoimmune diabetes model, effector T cell-derived TNF was shown to be essential for Treg development (Grinberg-Bleyer et al, 2010) . In addition, in vitro studies have found that addition of TNFRSF1B agonists accelerate IL2-driven human Treg expansion, consistent with the positive effects of TNF on Treg development (Okubo et al, 2013) . However, contrary to these data are reports suggesting a suppressive role of TNF on Treg compartment. These include in vitro data showing that addition of TNF or agonistic antibody to TNFRSF1B can reverse the suppressive function of Tregs by downmodulating FOXP3 expression (Valencia et al, 2006; Nie et al, 2013) . In addition, increased frequency of circulating of Treg subset lacking expression of IKZF2 (also termed Helios), a transcription factor that was originally reported as a marker that could distinguish natural from induced Tregs (Shevach & Thornton, 2014) have been described in patients with rheumatoid arthritis (RA) responsive to anti-TNF treatment (McGovern et al, 2012) . Consistent with these latter data, we recently showed that addition of TNF to in vitro cultures from healthy donors suppressed IKZF2-Treg proliferation whereas blocking anti-TNF antibodies preferentially increased proliferation of the IKZF2-Treg subset . It is not currently known whether TNF blockade has a positive or negative effect on Treg compartment, and its IKZF2+ and IKZF2À subsets in ITP patients. There are currently several TNF blockers in the clinic for treatment of various disease indications (Palladino et al, 2003) . Since their use was efficacious in four treated ITP patients (McMinn et al, 2003; Litton, 2008) , a detailed examination of the effect of TNF on Tregs in ITP patients may not only help to dissect the mechanism of Treg dysfunction in ITP patients but also provide a potential therapeutic target for ITP patients. In the current study, we measured TNF levels in circulating CD4+ T cells and monocytes from ITP patients and compared the effect of TNF blockade on Treg subsets between ITP patients and healthy controls using an in vitro T cell-monocyte co-culture system.
Materials and methods

Human samples
All the studies were approved by the Institutional Review Boards of the New York Blood Center and Weill Cornell Medical School. Peripheral blood was obtained after consent from 40 patients with ITP (Patients 1-40, Table I ). All of the patients had chronic ITP (defined >1 year since diagnosis, age range 15-60 years old, Table I ), except three (Patients 20, 22 and 23) who were in remission having platelet counts >100 9 10 9 /l for several months at the time of the blood draw. In some of the assays, we sampled blood from patients who had not received any ITP treatments for various lengths of time (Table I) . Patients who were on ITP treatment were exclusively on US Food and Drug Administration (FDA)-approved thrombopoietic agents (Romiplostim or Promacta) at the time of blood sampling (Table I) . Not all patients were analysed in every assay ( Table I) . As a control, peripheral blood samples were obtained from closely age-matched healthy volunteer donors of the New York Blood Center.
Cell isolation and purification
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll (GE Healthcare, Port Washington, NY, USA) density centrifugation and subjected to cell subset purification by magnetic beads (all from Miltenyi Biotec, Auburn, CA, USA) for isolation of total T cells and monocytes using the PAN T cell isolation kit and CD14 microbeads, respectively (purity>95% for both). For some studies, CD4+ cells were first enriched from PBMCs using magnetic beads, stained with anti-CD25-allophyocyanin (APC) (BD Biosciences, San Jose, CA, USA) and subjected to cell sorting to purify CD4 + CD25 À T cells (>95%, data not shown). À cells was measured following stimulation with phorbol myristate acetate (PMA, 0Á25 lg/ml; Sigma-Aldrich, St. Louis, MO, USA) and ionomycin (0Á375 lg/ml, Sigma-Aldrich) in the presence of GolgiPlug at 37°C for 5 h, after which the cells were fixed and permeabilized following manufacturer's instructions followed by intracellular staining with anti-TNF antibody (BD Biosciences). To measure TNFRSF1B expression levels on Tregs, PBMCs were first stained with anti-CD4, anti-CD25 and anti-TNFRSF1B-biotin (clone hTNFR-M1, BD Biosciences) for 15 min, washed several times followed by incubation with Streptavidin-PE-Cy7 (eBioscience) for another 15 min. After that, the cells were subjected to intracellular staining for FOXP3 and IKZF2 as described above.
T cell and monocyte stimulation assays
Statistical analysis
Data are expressed as mean values AE standard error of the mean (SEM). Statistical significance of differences between groups was determined by Mann-Whitney test and statistical significance of differences of paired data were determined by (Fig 2 and 3 
Results
ITP CD4+ T cells express higher levels of TNF
Circulating TNF levels are elevated in ITP patients (Culic et al, 2013; Jernas et al, 2013; Talaat et al, 2014) , but their levels in TNF expressing cells, such as CD4+ cells, has not been previously described in this patient population. We therefore measured TNF levels in CD4+ T cells from a group of patients with chronic ITP (n = 23; median age 36, range 15-60 years; 15 males and 8 females with median platelet count 27 9 10 9 /l, range 8-466 9 10 9 /l; 14 were splenectomized), who had been without any ITP treatment for at least 2 weeks prior to the blood draw (Table I) . Included in this analysis were five patients with platelet counts >100 9 10 9 /l; Patients 11 and 21
had stopped treatment with thrombopoietic agents two and three weeks, respectively, prior to the blood draw and patients 20, 22 and 23 were in remission. (Fig 1A-B) from ITP patients than from healthy controls (n = 20, P = 0Á02). Sub-analysis of CD4+TNF+ percentages in patients who had been off ITP treatment for ≥2 months (32Á4 AE 5Á0%, n = 10, Patients 3, 5, 7, 10, 17, 18, 19, 20, 22 and 23 ) as compared to those in healthy donors (19Á1 AE 2Á4%, n = 10) also revealed significant differences between the two groups (P = 0Á02). In addition, the cohort that had been off ITP treatment for ≥2 months had similar levels of CD4+TNF-a+ as patients without ITP treatment for ≤1 month (28Á4 AE 4Á9%, n = 13, P = 0Á4) or ≤3 weeks (29Á7 AE 9Á0%, n = 6, Patients 6, 8, 11, 13, 15, 21, P = 0Á9), suggesting that the length of time off ITP treatment did not affect CD4+TNF+ levels. Moreover, CD4+TNF+ cell frequencies were comparable, regardless of whether the patients had undergone splenectomy or not (Fig 1C) . Similarly, analysis of a subset of patients (n = 11, Patients 1-11) did not reveal any significant difference in the levels of CD4+TNF levels before and during treatment with thrombopoietic agents (Fig 1D) . In addition, comparison of our 'off treatment' patient cohort (n = 23) and a separate group of patients with chronic ITP on thrombopoietic agents (n = 8; Patients 24-31: median age 41, range 19-56 years; 2 males and 6 females with median platelet counts of 85 9 10 9 / l, range 35-154 9 10 9 /l; 4 were splenectomized, Table I ) also indicated similar overall frequency of TNF+ cells in sorted CD4 + CD25 À cells as patients without ITP treatment (Fig 1E) , suggesting that these drugs may not affect TNF levels in ITP CD4+ T cells. In some patients, we also measured circulating Treg frequencies, classically defined as CD25 hi FOXP3+ cells in CD4+ T lymphocytes (Table I , % Tregs) and found a trend toward negative correlation between frequencies of CD4+TNF+ cells and Tregs (Fig 1F,  P = 0Á03) , consistent with the reported inhibitory effect of TNF on FOXP3 expression (Valencia et al, 2006; Nie et al, 2013) . Given that PMA/ionomycin induces T cell receptor (TCR)-independent activation of T cells, we also checked TNF levels in CD4+ T cells stimulated using anti-CD3 antibodies (i.e., TCR-dependent activation) for 7 days in the presence of autologous monocytes (Fig 1G) in a smaller group of patients (n = 8, Table I ) as well as in healthy controls (n = 9). Similar to the PMA/ionomycin data, we found a higher frequency of TNF+CD4+ T cells following anti-CD3/monocyte stimulation in ITP patients as compared to healthy controls (Fig 1H, ' Total CD4+'). Given that T cells proliferate when activated through anti-CD3 and monocytes, we also compared the frequency of divided CD4+ T cells (CFSE lo ) that express TNF and found a higher frequency of these divided cells in the ITP patient group (Fig 1G-H , 'CD4+CFSE lo ').
Anti-TNF antibodies induce a strong Treg expansion in ITP patients
We have previously shown that in anti-CD3 stimulated T cell cultures from healthy donors, addition of TNF cytokine inhibits proliferation of the IKZF2-Tregs subset, which was originally reported to represent inducible Tregs (Shevach & Thornton, 2014) whereas antibody blocking with anti-TNF increases IKZF2-Treg expansion . Given that our above data indicate that CD4+TNF+ frequencies can be negatively associated with circulating Tregs in ITP patients, we hypothesized that the higher TNF levels may contribute to lower Tregs in ITP patients and that antibody neutralization with anti-TNF would have a more pronounced effect on proliferation of ITP Tregs. As a first step to test whether TNF blockade has an effect on Treg proliferation in patients with ITP, we randomly selected patients, regardless of their CD4+TNF+ levels (Table I) . Purified CFSE-labelled total T cells from ITP patients (n = 8) were stimulated with anti-CD3 in the presence of purified, autologous peripheral monocytes without or with anti-TNF antibody for 7 days. Although CD4+ T cell proliferation was not affected after blocking with anti-TNF (P = 0Á35), ITP Treg expansion, as measured by the frequency of CFSE lo FOXP3+ in CD4+ T cells, was significantly increased (>2-fold of IgG control, P = 0Á002, Fig 2A-C) , specifically in the IKZF2À Treg subset (Fig 2D-E) . Furthermore, expansion of Tregs, including both IKZF2+/ À subsets, was significantly higher in coculture from ITP patients as compared to healthy controls ( Fig 2F) . As these studies were performed using total T cells in the T cellmonocyte cocultures, it was unclear whether the anti-TNF treatment affected the expansion of pre-existing Tregs or their conversion from effector T cells. To distinguish between these two possibilities, we compared the effects of anti-TNF blockade in T cell-monocyte cocultures from four ITP patients (Patients 3, 29, 33 and 34, (Fig 2G) .
TNF blockade with anti-TNFRSF1B, but not anti-TNFRSF1A affects Treg proliferation in ITP patients
To determine the relative role of each of the two TNF receptors, TNFRSF1A and TNFRSF1B, on Treg expansion in ITP patients, we used specific neutralization antibodies in our coculture assays. Whereas anti-TNFRSF1A antibody treatment did not alter Treg expansion (Fig 3A-B) , anti-TNFRSF1B treatment induced a strong Treg expansion, almost doubling their proliferation (Fig 3C) . These data indicate that TNF inhibits Treg expansion through TNFRSF1B but not Table I ). (C) Frequency of CD4+TNF+ cells in the same cohort of patients as in B but grouped based on whether they had not or had undergone splenectomy. (D) To determine the effect of thrombopoietin (THPO) agent treatment, frequency of CD4+TNF+ cells in 11 patients (Patients1-11, Table I ) off treatment ('No') and on treatment with THPO agents for at least 2 weeks at the time of the blood draw ('Yes') were compared. (E) Comparison of CD4+TNF+ cell frequencies in the same cohort of patients as in B who were all off treatment ('No') vs a separate group of patients (Patients 24-31, Table I ) who were on treatment with THPO agents for at least 2 weeks at the time of the blood draw ('Yes'). TNFRSF1A. Although in healthy controls treatment with antibodies against TNFRSF1B increased IKZF2À Treg expansion with little effect on IKZF2+ Treg expansion, anti-TNFRSF1B treatment increased both IKZF2+/ À subsets in ITP patients, suggesting that its effect is more pronounced in ITP patients as compared to healthy controls (Fig 3D) . Given that ITP Tregs are more sensitive to blockade with anti-TNFRSF1B, we examined the relative expression levels of TNFRSF1B on Tregs, classically defined as CD25 Tregs were TNFRSF1B-positive with slightly higher TNFRSF1B levels on IKZF2-Tregs as compared to IKZF2+ Tregs (Fig 4A-B) . However, ITP patients expressed higher levels of TNFRSF1B on Tregs including both IKZF2+/ À subsets (Fig 4B) , consistent with their higher sensitivity to TNF regulation as compared to Tregs from healthy controls.
Discussion
In this study, overall higher levels of TNF expression were detected in CD4+ T cells from patients with chronic ITP and these levels correlated negatively with peripheral Treg frequencies. Furthermore, using an in vitro T cell proliferation assay with purified T cells and monocytes, a robust increase in Treg expansion, including both IKZF2+/ À Treg subsets, was detected following TNF blockade in ITP patients as compared to healthy controls. The expanded cells were derived from the pre-existing pool of Tregs rather than de novo-induced Tregs. Antibody neutralization with anti-TNFRSF1B, but not anti-TNFRSF1A, increased Treg proliferation, suggesting that the effect of anti-TNF treatment on Tregs was mediated through TNFRSF1B. Interestingly, we found elevated levels of TNFRSF1B on Tregs from ITP patients, which may explain the increased susceptibility of patient Tregs to the actions of TNF blockade. As TNF can down-modulate the function of human Tregs (Valencia et al, 2006; Nie et al, 2013) , our current data raises the possibility that heightened sensitivity of Tregs due to the combined effects of elevated receptor expression (TNFRSF1B) and ligand pool (TNF) may contribute to defective Treg compartment in ITP patients. Although the current study was performed using samples from patients with a range of platelet counts, including some patients who were in remission, and the TNF blockade experiments included analysis of patient samples with both high and low CD4+TNF-a levels, it is likely that patients with the most severe thrombocytopenia would probably have the most dysfunctional T cells and therefore such patients would most benefit from the use of TNF blockers. It should be noted that our previous data suggest that patients treated with thrombopoietin (THPO) agents have an improved Treg compartment (Bao et al, 2010) . However, we did not find any difference in TNF+CD4+ T cells in our cohort of patients treated with THPO agents as compared to those off treatment. These data suggest that the effect of THPO agents on the Treg compartment is not mediated through TNF, raising the possibility that combining TNF blocker drugs with THPO agents might enable improvement of the Treg compartment through different synergistic mechanisms to restore the immune balance in these patients. Currently, TNF blockade strategies involve antibodies against TNF, such as the mouse-human chimeric antibody (infliximab), fully humanized antibodies (Adalimumab and + Tregs and IKZF2+/À subsets are shown in unstimulated PBMCs from healthy controls 'HD' (n = 6) and ITP patients (n = 7). Data are expressed as mean values AE standard error of the mean; P values were calculated by the Mann-Whitney test. Golimumab), PEGylated Fab fragment (Certolizumab) or the use of soluble TNF receptor, including Etanercept, which is a fusion protein consisting of the extracellular portion of the TNFRSF1B linked to the Fc region of the human IgG1. With respect to mechanism of action, it should be noted that TNF receptor drugs, such as Etanercept, block the action of both TNF and LTA (TNFB, TNF-b), which share the same receptors, whereas antibodies against TNF are specific to TNF. In fact, treatment efficacy appears to differ depending on the TNF blocker used, which is partly explained by differences in their mechanism of action, although clinical outcomes are also associated with the underlying disease. (Mpofu et al, 2005) For example, all TNF blockers are highly effective in RA, but in Crohn disease there is a clear clinical benefit with infliximab but not etanercept (Targan et al, 1997; Sandborn et al, 2001 ) and the latter treatment exacerbates the pathology in multiple sclerosis. (Ghosh, 2012) A systematic characterization of Treg compartment in these patients has not been reported. Based on our data, we propose that the discrepancies in clinical outcomes with the TNF blockers may be partly due to differences in effectiveness of the drugs in improving the Treg compartment in different disease settings. For example, we found that anti-TNF treatment in cocultures from healthy donors reduced IKZF2+ Treg expansion, but increased IKZF2-Treg proliferation, such that the net effect of anti-TNF on overall Treg proliferation was minimal. In contrast, anti-TNF antibodies doubled the total ITP Treg expansion. Moreover, anti-TNFRSF1B antibodies, which block the binding of TNF and LTA to their receptor, only targeted IKZF2-Treg subset proliferation in healthy donors with little effect on IKZF2+ Tregs, but increased the expansion of both IKZF2+ and IKZF2À Treg subsets in ITP patients. Interestingly, etanercept treatment was efficacious in four treated ITP patients (McMinn et al, 2003; Litton, 2008) . Our data thus raise the possibility that responsiveness to TNF blockers in these ITP patients might have been due to an effective increase in Treg subsets.
In summary, we have shown that in vitro TNF blockade can induce much stronger Treg expansion ex vivo in ITP patients as compared to healthy controls, partly due to the potentially higher sensitivity of ITP Tregs to TNF mediated inhibition. These findings raise the possibility that TNF blockers, through their ability to increase Treg subset proliferation, may be efficacious in ITP patients.
